Financials and Estimates

Financials and Estimates

Figures converted from Indonesian rupiah at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

JPFA's income statement is cyclical mainly through the margin. Revenue has risen every year for a decade, from about $1.9bn in 2016 to $3.64bn in 2025, while the operating margin swung between 4.3% and 11.7% and dragged reported profit with it [1]. Earnings now convert fully to cash, the balance sheet has deleveraged into the record year, and consensus models a high plateau rather than a fall. This tab lays out the three years of actuals behind the record, plus the forward estimates, and flags where each could break.

Source: FY2025 Annual Report, Financial Highlights and Key Financial Ratios [2].

The cycle lives in the margin

Over ten years JPFA's revenue never fell — not in the 2020 pandemic year, not in the 2023 poultry downturn. What moved was the operating margin, from a 11.7% high in 2016 to a 4.3% trough in 2023 and back to 10.2% in 2025 [3]. Because most of the chain sells live birds, day-old chicks and feed into a spot market, a few percentage points of margin is the difference between a $0.06bn profit year and a $0.24bn one on a barely-changed top line [4].

Source: FY2025 Annual Report financial highlights [5]; operating income and net sales for FY2016–FY2024 as reported in the audited consolidated financial statements.

The three-year window behind the record is stark. Operating margin ran 4.3% → 9.1% → 10.2%; net profit margin 1.8% → 5.8% → 7.1%; return on equity 6.7% → 19.4% → 21.4%; EPS $0.005 → $0.016 → $0.021 [6]. Gross profit alone rose from $0.49bn to $0.79bn on cost of goods sold that grew only about $0.23bn — operating leverage working in the company's favour as broiler and day-old-chick prices recovered against feed cost [7].

Source: FY2025 Annual Report, Financial Highlights [8] and Key Financial Ratios [9].

Earnings that turn into cash

For a reader whose first calibration is bankruptcy risk, the more useful test than reported profit is whether that profit becomes cash. Across FY2021–FY2025 JPFA generated about $0.90bn of operating cash flow against about $0.76bn of total net profit — cumulative cash conversion of about 1.19x [10]. The record is not smooth: in the 2021 expansion, operating cash flow was only $0.05bn against $0.15bn of profit as working capital and biological inventory built; in the 2023 trough, cash ran well ahead of earnings as that working capital released [11]. Over a full cycle, though, the profit is real cash, not an accrual.

Source: FY2025 Annual Report, Consolidated Statement of Cash Flows [12]; free cash flow derived as operating cash flow less capital expenditure.

Free cash flow tells the capital-intensity story. It was negative in FY2021 and FY2022 while the group spent $0.1bn–$0.15bn a year on capacity, then turned firmly positive: $0.20bn in FY2024 and $0.15bn in FY2025 after $0.15bn of capex [13]. The five-year cumulative is about $0.3bn of free cash — enough to cover the roughly $0.05bn paid out in dividends each of the last two years with room to spare [14]. The counter-fact worth keeping: this is peak-margin cash. In a repeat of 2021–2022, feeding the working-capital cycle can turn free cash flow negative even without a loss.

Balance sheet: deleveraged into the record

JPFA ended FY2025 with total equity of $1.20bn against $1.20bn of total liabilities — a total-liabilities-to-equity ratio of 1.0x, down from 1.4x in 2023 — and interest-bearing-debt-to-equity of 0.6x, down from 0.9x [15]. Gross interest-bearing debt of roughly $0.71bn, set against $0.21bn of cash, leaves net debt near $0.50bn — about 0.4x equity [16]. For a business earning a 21% return on that equity, solvency is not the near-term question.

Source: derived from FY2025 Annual Report — cash and borrowings detail [17] and disclosed ratios [18].

One line does deserve a pause. The current ratio fell from 1.8x to 1.3x, and current liabilities jumped 78% to $0.99bn [19]. Almost all of that is one item: the US$350 million 5.375% Sustainability-Linked Bond, issued in 2021 and maturing 23 March 2026, reclassified from long-term to current — $0.35bn [20]. It is not distress, and it is funded two ways: the company built its cash balance 162% to $0.21bn, holding US dollars specifically to repay the bond [21], and it arranged bank facilities expressly to refinance the US$350 million notes falling due 21 March 2026 [22].

Stripping the reclassified bond out of current liabilities returns the current ratio to about 2.0x — the level of the prior two years [23]. The live confirmation is the 30 June 2026 statement, not yet published at the time of writing, which will show the bond settled.

Dividends track the cycle

JPFA pays out on a policy of roughly a third to a half of profit, so the dividend rises and falls with the margin. Dividend per share ran $0.001 for FY2019 (a 13% payout), $0.003 for FY2020 (51%), $0.004 for FY2021 (35%) and $0.003 for FY2022 (41%) [24][25], before the recovery lifted the FY2024 distribution to a record $0.009 — a 55% payout, $0.10bn in total [26].

Source: FY2021 [27], FY2023 [28] and FY2025 [29] Annual Reports. FY2023 (trough EPS $0.005) omitted; the FY2025 dividend is set at the 2026 AGM.

On the same ~50% policy, FY2025's record EPS of $0.021 points to a materially larger distribution once declared, and the cash-flow statement already shows $0.05bn of dividends actually paid during 2025 [30]. The reader's own margin-of-safety test cuts both ways: the yield is real but variable, and a down-cycle would shrink it exactly when the share price is likely weakest.

What consensus expects

Thirteen sell-side analysts carry a "Strong Buy" and a mean 12-month target of $0.174, about 43% above the 3 August 2026 close of $0.122 (Company and Cycle sets out the price history). Their forward numbers, though, describe a plateau, not another leg up: net sales of $3.60bn / $3.88bn / $4.28bn and EPS of $0.021 / $0.022 / $0.023 for FY2026–FY2028, growth decelerating to mid-single digits by FY2028.

Source: FY2025 actual from the Annual Report [31]; FY2026–FY2028 consensus from StockAnalysis and MarketScreener, snapshot 23 July 2026 (as reported). Forward P/E computed on the 3 August 2026 close of $0.122.

Two things sit in tension inside these numbers. First, consensus and the market disagree about the same company: analysts model EPS holding above $0.021 through 2028, which would put the stock at roughly 5x forward earnings, yet the market pays about 6x trailing and trades below the 2025 year-end close [32]. If the plateau holds, the multiple is low for the earnings; if 2025–2026 is the cycle peak, a low multiple on peak earnings is the ordinary result. Second, the FY2026 consensus of $0.021 already looks conservative against a trailing-twelve-month EPS of about $0.024 struck after a first-quarter 2026 in which profit to owners roughly tripled year on year — the estimate may lag the most recent print rather than lead it.

What would change the read

The read is most sensitive to where the operating margin settles. The mid-cycle of the last decade sat closer to 6–8% than to the 10.2% of FY2025; a reversion toward that band would pull EPS back toward $0.009–$0.015 and make today's ~6x trailing multiple fair rather than cheap. The evidence for durability is that the recovery held for two full years and that revenue mix keeps shifting toward processed and consumer products ($0.64bn in FY2025, the fastest-growing segment) [33]. The evidence against it is that the margin has round-tripped this far before. The near-term tells are the 30 June 2026 consolidated statement due in August 2026 and Indonesian day-old-chick and broiler spot prices against the corn and soybean-meal cost that drives the whole chain — the segment mechanics a later chapter should take up.